Privately-held CVRx Inc., developer of the Barostim Neo minimally invasive implantable system with separate indications for heart failure and resistant hypertension, has scored a major coup in securing $113 million in new funding in what remains a difficult market for medical device investment. The financing was led by Johnson & Johnson Development Corp., the venture arm of Johnson & Johnson.
Of equal significance, CVRx has also this year become one of the first beneficiaries of the US FDA’s Expedited Access...


![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)
